Pinterest • The world’s catalog of ideas

Stock Market Analysis for November 2nd 2016 FOMC // Market Review // Valeant Pharmaceuticals - YouTube

Valeant Pharmaceuticals Intl Inc: VRX Stock Is Getting Crushed … Again

Valeant Pharmaceuticals Intl Inc (VRX) Misses Q3 Earnings, Shares Tank Over 11%

Mizuho raised its rating on Valeant Pharmaceuticals (VRX) stock to 'neutral' from 'underperform,' just one week after downgrading the stock on criminal investigation charges.

In 2012, Valeant Pharmaceuticals, a giant Canadian drug company, purchased Medicis and its flagship product Solodyn® for 2.6 billion dollars. Solodyn® was Medicis' biggest money-maker, accounting for around 40% of Medicis' sales.

Advanced Dermatology & Cosmetic Surgery, (ADCS Clinics) Continues To Expand Provider Talent Base And Education Efforts

Valeant Pharmaceuticals Intl Inc: More Bad News for VRX Stock Buz Investors BULLISH Bad News for VRX Stock (NYSE:VRX) can’t seem to catch a break. The company dropped another 4.75% today as the embattled pharmaceutical producer was once again downgraded to “Underperform” from “Neutral” by Irina Koffler atMizuho Securities Co., Ltd., where she believes #InvestorsBuz #Valeant #Pharmaceuticals #Bad #News

Valeant Pharmaceuticals (VRX) to Name New CEO as Pearson Still in Hospital

Valeant Pharmaceuticals Intl Inc (VRX): Should You Invest?